From: Dyslipidemia and non-small cell lung cancer risk in Chinese population: a case-control study
Variable | No. of Patients (%) | P value | ||
---|---|---|---|---|
838 | Controls (n = 414) | NSCLC (n = 424) | ||
Age (years) | 0.886 | |||
≤ 45 | 36 (62.9) | 19 (4.6) | 17 (4.0) | |
> 45& ≤ 65 | 451 (37.1) | 224 (54.1) | 227 (53.5) | |
> 65 | 351 (37.1) | 171 (41.3) | 180 (42.5) | |
Gender | 0.321 | |||
Male | 553 (62.2) | 280 (67.6) | 273 (64.4) | |
Female | 285 (37.8) | 134 (32.4) | 151 (35.6) | |
BMI, Kg/m2 | 0.451 | |||
≤ 25 | 579 (69.1) | 281 (67.9) | 295 (70.3) | |
> 25 | 259 (30.9) | 133 (32.1) | 126 (29.7) | |
Smoking status | ||||
No | 663 (79.1) | 383 (93.0) | 280 (98.5) | < 0.001* |
Ever/current | 175 (20.9) | 31 (7.0) | 144 (1.5) | |
Alcohol consumption | 0.859 | |||
No | 674 (80.4) | 334 (11.8) | 340 (23.1) | |
Yes | 164 (19.6) | 80 (44.1) | 84 (50.9) | |
Hypertension | 0.289 | |||
No | 589 (70.3) | 298 (72) | 291 (68.6) | |
Yes | 249 (29.7) | 40 (28) | 108 (31.4) | |
Diabetes | 0.225 | |||
No | 787 (93.9) | 393 (78.9) | 394 (92.7) | |
Yes | 51 (6.1) | 21 (21.1) | 30 (7.3) | |
Statins use | 0.583 | |||
No | 813 (94.9) | 403 (87.3) | 410 (96.5) | |
Yes | 25 (5.1) | 11 (12.7) | 14 (3.5) | |
Lipid profiles, mmol/L | ||||
TC | 0.295 | |||
Normal (< 5.2) | 632 (75.5) | 313 (75.6) | 319 (75.4) | |
BH (≥5.2& < 6.2) | 159 (19) | 83 (20.0) | 76 (18.0) | |
High (≥6.2) | 46 (5.5) | 18 (4.4) | 28 (6.6) | |
LDL-C | 0.691 | |||
Normal (< 3.4) | 772 (29.1) | 382 (92.3) | 390 (92.0) | |
BH (≥3.4& < 4.1) | 58 (55.0) | 27 (6.5) | 31 (7.3) | |
High (≥4.1) | 8 (15.9) | 5 (1.2) | 3 (0.7) | |
HDL-C | < 0.001* | |||
Low (< 1.0) | 244 (29.1) | 74 (17.9) | 170 (40.1) | |
Nomal (≥1.0& < 1.5) | 461 (55.0) | 260 (62.8) | 201 (47.4) | |
High (≥1.5) | 133 (15.9) | 80 (19.3) | 53 (12.5) | |
TG | 0.026 | |||
Normal (< 1.7) | 525 (62.6) | 278 (67.1) | 247 (58.3) | |
BH (≥1.7& < 2.3) | 159 (19.0) | 71 (17.1) | 88 (20.8) | |
High (≥2.3) | 154 (18.4) | 65 (15.7) | 89 (21.0) | |
Pathological type | ||||
squamous carcinoma | 139 (32.8) | |||
adenocarcinoma | 277 (65.3) | |||
others | 8(1.9) | |||
TNM stage | ||||
I | 202 (47.6) | |||
II | 85 (20.1) | |||
III | 115 (27.1) | |||
IV | 22 (5.2) |